Dina Ben Yehuda
Overview
Explore the profile of Dina Ben Yehuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pick M, Vainstein V, Goldschmidt N, Lavie D, Libster D, Gural A, et al.
Eur J Haematol
. 2018 Feb;
100(5):494-501.
PMID: 29453884
Objective: Daratumumab is a promising new antimyeloma agent. We report a single center "real-world" series of multiple myeloma (MM) and amyloidosis (AL) patients treated with daratumumab. Methods: Forty-one patients were...
12.
Kleinstern G, Abu Seir R, Perlman R, Khatib A, Abdeen Z, Elyan H, et al.
PLoS One
. 2017 Feb;
12(2):e0171709.
PMID: 28196110
Background: Risk factors for B-cell non-Hodgkin lymphoma (B-NHL) have not been assessed among Palestinian Arabs (PA) and Israeli Jews (IJ). Methods: In a case-control study we investigated self-reported medical and...
13.
Dimopoulos M, Oriol A, Nahi H, San-Miguel J, Bahlis N, Usmani S, et al.
N Engl J Med
. 2016 Oct;
375(14):1319-1331.
PMID: 27705267
Background: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 trial,...
14.
Kleinstern G, Abu Seir R, Perlman R, Abdeen Z, Khatib A, Elyan H, et al.
Haematologica
. 2016 Apr;
101(7):e303-5.
PMID: 27102500
No abstract available.
15.
Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Yehuda D, et al.
Haematologica
. 2015 Apr;
100(7):955-63.
PMID: 25911553
We investigated rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (n=662) or follicular lymphoma grade 3b (n=21) in first complete remission. Patients were randomized to rituximab maintenance (n=338)...
16.
Palumbo A, Cavallo F, Gay F, Di Raimondo F, Yehuda D, Petrucci M, et al.
N Engl J Med
. 2014 Sep;
371(10):895-905.
PMID: 25184862
Background: This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared...
17.
Ganzel C, Pogrebijsky G, Krichevsky S, Neuman T, Yehuda D
Exp Hematol
. 2012 Jun;
40(9):698-704.e2.
PMID: 22659385
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have traditionally been considered as two distinct entities. However, there are rare reports of patients that, over time, develop both diseases. It remains...
18.
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci M, Catalano J, et al.
N Engl J Med
. 2012 May;
366(19):1759-69.
PMID: 22571200
Background: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed...
19.
Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al.
Blood
. 2011 Aug;
119(4):933-9.
PMID: 21835953
Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE). This prospective, open-label, randomized substudy of a...
20.
Meirow D, Hardan I, Dor J, Fridman E, Elizur S, Raanani H, et al.
Hum Reprod
. 2008 Mar;
23(5):1007-13.
PMID: 18344563
Background: Storing ovarian tissue for fertility preservation in cancer patients carries the risk of the presence of malignant cells that could lead to recurrence of cancer after reimplantation. Methods to...